|Test Name||LIQUID BIOPSY, cfDNA, EGFR|
|Clinical Utility||• Simple non-invasive blood draw.
• Not dependent on availability of tissue sample.
• Utilizes circulating cell-free DNA (cfDNA) to provide comprehensive tumor mutational. profle.
• This is an in-house developed test useful. for the detection of exon 19 deletion (p.E746_A750deletion), Exon 20 point mutation (T790M) and Exon 21 point mutation (L858R).
|Patient Selection||Patients with limited traditional. cancer therapy options:
• Metastatic Cancer
• Refractory or resistant cancer
|Technology||Digital. Droplet PCR|
|TAT||Mon / Thu 9 am; Report Fri / Tue|
|Specimen||10 mL Whole blood in 1 Streck tube.|
Comparison between tissue biopsy & liquid biopsy
|Tissue Biopsy||Liquid Biopsy|
|Lack of tumor heterogeneity||Representation of intra-tumoral complexity|
|Not an option in severely ill patients||Can be a substitute for primary biopsy in severely ill patients|
|No periodic monitoring for progression/ recurrence||Dynamic monitoring of molecular changes for progression/recurrence|
|Obtained by surgery, an expensive procedure. Not easily obtained||Body fluid/blood is collected by a simple inexpensive procedure. Easily obtained|
|Some pain and risk involved||Minimal pain and risk involved|
|Invasive and uncomfortable (possibility of clinical complications)||Minimally invasive|
When to use Liquid Biopsy?
• Patients under treatment to monitor therapy response and drug resistance
• Patients whose tumor is inaccessible
• Patients in remission for monitoring cancer recurrence
• Patients diagnosed with cancer for molecular profiling and therapy match
• Patients who have failed other treatments
• Patients with metastatic cancer